{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:44:07Z","timestamp":1793166247665,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Management of\u00a0recurrent acromegaly is challenging for both neurosurgeons and endocrinologists. Several treatment options including repeat surgery, medical therapy, and radiation are offered for such patients. The efficacy of these modalities for the treatment of recurrence has not been studied previously in the literature. In this study, we aim to systematically review the existing cases of recurrence and come to a conclusion regarding the appropriate treatment in such cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic review was performed through PubMed, Scopus, Web of Science, and Cochrane database to identify studies reporting the treatment outcome of recurrent acromegaly patients. Using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, the included studies were reviewed for primary and secondary treatment, complications, and outcomes of the secondary treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The systematic review retrieved 23 records with 95 cases of recurrent acromegaly. The mean time of recurrence was 4.16 years after the initial treatment. The most common primary treatment was surgery followed by radiotherapy. The remission rate was significantly higher in medical and radiotherapy compared to surgical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In cases of recurrent acromegaly, the patient may benefit more from radiotherapy and medical therapy compared to surgery. As the quality of evidence is low on this matter feature studies specifically designed for recurrent patients are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01533-w","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T05:02:24Z","timestamp":1706245344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recurrent acromegaly: a systematic review on therapeutic approaches"],"prefix":"10.1186","volume":"24","author":[{"given":"Seyed Farzad","family":"Maroufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadmahdi","family":"Sabahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Sahab","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Samadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Dabecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badih","family":"Adada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla M.","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Borghei-Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"issue":"1","key":"1533_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4\u20139.","journal-title":"Pituitary"},{"issue":"3","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000497214","volume":"108","author":"M Hage","year":"2019","unstructured":"Hage M, Kamenick\u00fd P, Chanson P. Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology. 2019;108(3):244\u201355.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jocn.2010.10.003","volume":"18","author":"LA Del Porto","year":"2011","unstructured":"Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J Clin Neurosci. 2011;18(2):181\u201390.","journal-title":"J Clin Neurosci"},{"key":"1533_CR4","doi-asserted-by":"publisher","first-page":"540398","DOI":"10.1155\/2012\/540398","volume":"2012","author":"G Lugo","year":"2012","unstructured":"Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"1533_CR5","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","volume":"105","author":"A Ghajar","year":"2020","unstructured":"Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, et al. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):e532\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1533_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1210\/jc.2003-031316","volume":"89","author":"PU Freda","year":"2004","unstructured":"Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of \u201cabnormal\u201d nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89(2):495\u2013500.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3\u20134","key":"1533_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000181885","volume":"35","author":"M Buchfelder","year":"1991","unstructured":"Buchfelder M, Brockmeier S, Fahlbusch R, Honegger J, Pichl J, Manzl M. Recurrence following transsphenoidal surgery for acromegaly. Hormone Res Paediatr. 1991;35(3\u20134):113\u20138.","journal-title":"Hormone Res Paediatr"},{"issue":"2","key":"1533_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/eje.1.01968","volume":"153","author":"G Besser","year":"2005","unstructured":"Besser G, Burman P, Daly A. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153(2):187\u201393.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1533_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3171\/jns.2003.98.4.0719","volume":"98","author":"MD Krieger","year":"2003","unstructured":"Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. J Neurosurg. 2003;98(4):719\u201324.","journal-title":"J Neurosurg"},{"issue":"1","key":"1533_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1533_CR11","doi-asserted-by":"publisher","first-page":"M107","DOI":"10.1530\/EJE-15-0616","volume":"173","author":"O Koulouri","year":"2015","unstructured":"Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA, et al. A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur J Endocrinol. 2015;173(4):M107\u201320.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1533_CR12","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1210\/jcem.85.7.6699","volume":"85","author":"NR Biermasz","year":"2000","unstructured":"Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1533_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-09-1045","volume":"162","author":"S Roug","year":"2010","unstructured":"Roug S, Rasmussen \u00c5, Juhler M, Kosteljanetz M, Poulsgaard L, Heeb\u00f8ll H, et al. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Eur J Endocrinol. 2010;162(4):685.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1533_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3171\/jns.1998.88.6.1002","volume":"88","author":"AM Landolt","year":"1998","unstructured":"Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998;88(6):1002\u20138.","journal-title":"J Neurosurg"},{"issue":"1","key":"1533_CR15","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","volume":"98","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders RA, Van Der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1533_CR16","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1210\/jc.2010-0670","volume":"95","author":"L Katznelson","year":"2010","unstructured":"Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab. 2010;95(9):4114\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1533_CR17","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2010.7.FOCUS10168","volume":"29","author":"S Manjila","year":"2010","unstructured":"Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR. Pharmacological management of acromegaly: a current perspective. Neurosurg Focus. 2010;29(4):E14.","journal-title":"Neurosurg Focus"},{"issue":"1","key":"1533_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","volume":"20","author":"NA Tritos","year":"2017","unstructured":"Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129\u201335.","journal-title":"Pituitary"},{"issue":"6","key":"1533_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3171\/jns.1988.68.6.0854","volume":"68","author":"DA Ross","year":"1988","unstructured":"Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 1988;68(6):854\u201367.","journal-title":"J Neurosurg"},{"issue":"6","key":"1533_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/00000421-199212000-00003","volume":"15","author":"DJ Salinger","year":"1992","unstructured":"Salinger DJ, Brady LW, Miyamoto CT. Radiation therapy in the treatment of pituitary adenomas. Am J Clin Oncol. 1992;15(6):467\u201373.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1533_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3171\/jns.1996.85.2.0239","volume":"85","author":"H Long","year":"1996","unstructured":"Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg. 1996;85(2):239\u201347.","journal-title":"J Neurosurg"},{"issue":"10","key":"1533_CR22","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1210\/jcem.83.10.5111","volume":"83","author":"A Abosch","year":"1998","unstructured":"Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83(10):3411\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1533_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3171\/jns.1998.89.3.0353","volume":"89","author":"PU Freda","year":"1998","unstructured":"Freda PU, Wardlaw SL, Post K. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89(3):353\u20138.","journal-title":"J Neurosurg"},{"issue":"10","key":"1533_CR24","first-page":"3419","volume":"83","author":"B Swearingen","year":"1998","unstructured":"Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10):3419\u201326.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1533_CR25","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1210\/jcem.85.12.7042","volume":"85","author":"NR Biermasz","year":"2000","unstructured":"Biermasz NR, Van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab. 2000;85(12):4596\u2013602.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1533_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/jns.2002.97.3.0525","volume":"97","author":"BE Pollock","year":"2002","unstructured":"Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg. 2002;97(3):525\u201330.","journal-title":"J Neurosurg"},{"issue":"926","key":"1533_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1259\/bjr\/51245688","volume":"78","author":"MJ Acosta-Gomez","year":"2005","unstructured":"Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G, et al. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol. 2005;78(926):110\u20135.","journal-title":"Br J Radiol"},{"key":"1533_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3171\/sup.2006.105.7.31","volume":"105","author":"AM Landolt","year":"2006","unstructured":"Landolt AM, Lomax N, Scheib SG, Girard J. Gamma Knife surgery after fractionated radiotherapy for acromegaly. J Neurosurg. 2006;105:31\u20136.","journal-title":"J Neurosurg"},{"issue":"7","key":"1533_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4158\/EP.13.7.726","volume":"13","author":"JH Petit","year":"2007","unstructured":"Petit JH, Biller BMK, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007;13(7):726\u201334.","journal-title":"Endocr Pract"},{"issue":"6","key":"1533_CR30","first-page":"1262","volume":"62","author":"J Jagannathan","year":"2008","unstructured":"Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML. Gamma knife radiosurgery for acromegaly: Outcomes after failed transsphenoidal surgery. Neurosurgery. 2008;62(6):1262\u20139.","journal-title":"Neurosurgery"},{"issue":"7","key":"1533_CR31","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1210\/jc.2008-0135","volume":"93","author":"M Losa","year":"2008","unstructured":"Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 2008;93(7):2546\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1533_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1227\/NEU.0b013e3181ec4379","volume":"67","author":"S Yamada","year":"2010","unstructured":"Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery. 2010;67(4):949\u201356.","journal-title":"Neurosurgery"},{"issue":"2","key":"1533_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2265.2012.04492.x","volume":"78","author":"F Albarel","year":"2013","unstructured":"Albarel F, Castinetti F, Morange I, Conte-Devolx B, Gaudart J, Dufour H, et al. Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol. 2013;78(2):263\u201370.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1533_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13760-012-0128-8","volume":"113","author":"K Van Rompaey","year":"2013","unstructured":"Van Rompaey K, Unuane D, Moens M, Duerinck J, Poppe K, Velkeniers B, et al. Long-term follow-up results of multimodal treatment with initial surgical approach for acromegaly in a single center. Acta Neurol Belg. 2013;113(1):49\u201354.","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"1533_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0028-3886.111114","volume":"61","author":"SK Sankhla","year":"2013","unstructured":"Sankhla SK, Jayashankar N, Khan GM. Surgical management of selected pituitary macroadenomas using extended endoscopic endonasal transsphenoidal approach: early experience. Neurol India. 2013;61(2):122\u201330.","journal-title":"Neurol India"},{"issue":"1","key":"1533_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.wneu.2013.01.021","volume":"81","author":"M Shirvani","year":"2014","unstructured":"Shirvani M, Motiei-Langroudi R. Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients. World Neurosurg. 2014;81(1):125\u201330.","journal-title":"World Neurosurg"},{"issue":"1","key":"1533_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0033-1354578","volume":"75","author":"H Sun","year":"2014","unstructured":"Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. J Neurol Surg Part B, Skull Base. 2014;75(1):47\u201352.","journal-title":"J Neurol Surg Part B, Skull Base"},{"issue":"8","key":"1533_CR38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00381-014-2421-8","volume":"30","author":"S Sinha","year":"2014","unstructured":"Sinha S, Sarkari A, Mahapatra AK, Sharma BS. Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients. Childs Nerv Syst. 2014;30(8):1405\u201311.","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"1533_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-013-0502-4","volume":"17","author":"A Paluzzi","year":"2014","unstructured":"Paluzzi A, Fernandez-Miranda JC, Stefko ST, Challinor S, Snyderman CH, Gardner PA. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17(4):307\u201319.","journal-title":"Pituitary"},{"issue":"3","key":"1533_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12020-016-1081-8","volume":"56","author":"M Losa","year":"2017","unstructured":"Losa M, Spatola G, Albano L, Gandolfi A, Del Vecchio A, Bolognesi A, et al. Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas. Endocrine. 2017;56(3):595\u2013602.","journal-title":"Endocrine"},{"issue":"1","key":"1533_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3889\/oamjms.2020.4213","volume":"8","author":"M Ismail","year":"2020","unstructured":"Ismail M, Ragab OAAAM, Salama MM, Ayoub BM, Elmahdy W. Transcranial versus endoscopic transsphenoidal approaches in management of recurrent giant pituitary adenomas. Open Access Macedonian J Med Sci. 2020;8(1):273\u201380.","journal-title":"Open Access Macedonian J Med Sci"},{"issue":"4","key":"1533_CR42","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/jc.2004-2009","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1533_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s11102-015-0657-2","volume":"18","author":"TJ Reid","year":"2015","unstructured":"Reid TJ, Jin Z, Shen W, Reyes-Vidal CM, Fernandez JC, Bruce JN, et al. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary. 2015;18(6):808\u201319.","journal-title":"Pituitary"},{"issue":"5","key":"1533_CR44","doi-asserted-by":"publisher","first-page":"e12958","DOI":"10.1111\/jne.12958","volume":"33","author":"M Shen","year":"2021","unstructured":"Shen M, Chen Z, Shou X, He W, Qiao N, Ma Z, et al. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly. J Neuroendocrinol. 2021;33(5):e12958.","journal-title":"J Neuroendocrinol"},{"issue":"11","key":"1533_CR45","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1533_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JA, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552\u201361.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1533_CR47","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BM, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105(4):e937\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1533_CR48","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1210\/jc.2005-0901","volume":"90","author":"R Feelders","year":"2005","unstructured":"Feelders R, Bidlingmaier M, Strasburger C, Janssen J, Uitterlinden P, Hofland L, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005;90(12):6480\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1533_CR49","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1210\/jc.2004-1974","volume":"90","author":"CL Ronchi","year":"2005","unstructured":"Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab. 2005;90(3):1377\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1533_CR50","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2265.2007.02769.x","volume":"66","author":"CL Ronchi","year":"2007","unstructured":"Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A. Adequacy of current postglucose GH nadir limit (< 1 \u00b5g\/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol. 2007;66(4):538\u201342.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"1533_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11102-020-01094-4","volume":"24","author":"PU Freda","year":"2021","unstructured":"Freda PU, Bruce JN, Reyes-Vidal C, Singh S, DeLeon Y, Jin Z, et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary. 2021;24(2):170\u201383.","journal-title":"Pituitary"},{"issue":"3","key":"1533_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1046\/j.1365-2265.2002.01465.x","volume":"56","author":"NR Biermasz","year":"2002","unstructured":"Biermasz NR, Smit JW, Van Dulken H, Roelfsema F. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin Endocrinol. 2002;56(3):313\u20139.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1533_CR53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1677\/erc.0.0100611","volume":"10","author":"G Minniti","year":"2003","unstructured":"Minniti G, Jaffrain-Rea M, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer. 2003;10(4):611\u20139.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"1533_CR54","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1210\/jcem.86.9.7819","volume":"86","author":"J Kreutzer","year":"2001","unstructured":"Kreutzer J, Vance M, Lopes M, Laws E Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1533_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11102-016-0783-5","volume":"20","author":"ML Gheorghiu","year":"2017","unstructured":"Gheorghiu ML. Updates in outcomes of stereotactic radiation therapy in acromegaly. Pituitary. 2017;20(1):154\u201368.","journal-title":"Pituitary"},{"issue":"51","key":"1533_CR56","first-page":"107","volume":"10","author":"F Castinetti","year":"2010","unstructured":"Castinetti F, Brue T. Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat? Discov Med. 2010;10(51):107\u201311.","journal-title":"Discov Med"},{"issue":"4","key":"1533_CR57","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/cen.12938","volume":"84","author":"O Cohen-Inbar","year":"2016","unstructured":"Cohen-Inbar O, Ramesh A, Xu Z, Vance ML, Schlesinger D, Sheehan JP. Gamma knife radiosurgery in patients with persistent acromegaly or Cushing\u2019s disease: long-term risk of hypopituitarism. Clin Endocrinol. 2016;84(4):524\u201331.","journal-title":"Clin Endocrinol"},{"issue":"11","key":"1533_CR58","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.jocn.2012.11.026","volume":"20","author":"P Wilson","year":"2013","unstructured":"Wilson P, De-Loyde K, Williams J, Smee R. Acromegaly: a single centre\u2019s experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. J Clin Neurosci. 2013;20(11):1506\u201313.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"1533_CR59","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3171\/2017.2.JNS162673","volume":"129","author":"JP Almeida","year":"2018","unstructured":"Almeida JP, Ruiz-Trevi\u00f1o AS, Liang B, Omay SB, Shetty SR, Chen YN, et al. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature. J Neurosurg. 2018;129(2):404\u201316.","journal-title":"J Neurosurg"},{"issue":"1","key":"1533_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3171\/2014.3.JNS131532","volume":"121","author":"A Jahangiri","year":"2014","unstructured":"Jahangiri A, Wagner J, Han SW, Zygourakis CC, Han SJ, Tran MT, et al. Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations. J Neurosurg. 2014;121(1):67\u201374.","journal-title":"J Neurosurg"},{"key":"1533_CR61","doi-asserted-by":"publisher","first-page":"924589","DOI":"10.3389\/fendo.2022.924589","volume":"13","author":"DP Bray","year":"2022","unstructured":"Bray DP, Mannam S, Rindler RS, Quillin JW, Oyesiku NM. Surgery for acromegaly: Indications and goals. Front Endocrinol. 2022;13:924589.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1533_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","volume":"71","author":"CE Higham","year":"2009","unstructured":"Higham CE, Chung T, Lawrance J, Drake WM, Trainer PJ. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol. 2009;71(1):86\u201391.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1533_CR63","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1210\/clinem\/dgac037","volume":"107","author":"EC Coopmans","year":"2022","unstructured":"Coopmans EC, van der Lely AJ, Neggers SJCMM. Approach to the patient with treatment-resistant acromegaly. J Clin Endocrinol Metab. 2022;107(6):1759\u201366.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1533_CR64","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","volume":"14","author":"LF Grasso","year":"2015","unstructured":"Grasso LF, Auriemma RS, Pivonello R, Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf. 2015;14(8):1213\u201326.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"1533_CR65","doi-asserted-by":"publisher","first-page":"R551","DOI":"10.1530\/ERC-16-0151","volume":"23","author":"K \u00d6berg","year":"2016","unstructured":"\u00d6berg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016;23(12):R551\u201366.","journal-title":"Endocr Relat Cancer"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01533-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01533-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01533-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T06:03:35Z","timestamp":1706249015000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01533-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01533-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}